

Strategic Plan 2024-2029 Implementation Kick-off meeting, July 8, 2025

pharmacoepi.org

CONTENTS

- Introduction
- ISPE SP 2024-2029: from generation to implementation
- Objectives and Goals of the SP 2024-2029
- The Structure of the implementation plan
- Roles & Responsibilities
- Tools
- Q&A

Introduction

ISPE Strategic Planning Committee 2024-25





Ursula Kirchmayer, FISPE President-elect

Jennifer Christian, FISPE Vice President/Finance



Susan DosReis, FISPEYasser AlbogamiPublic Policy CmteGlobal Development Cmte



Daniela Moga, FISPE Membership Cmte



Blánaid Hicks



Jennifer Lund, FISPE Board of Directors



Elisabetta Patorno, FISPE Board of Directors



Interim-Executive Secretaries

θ7

ISPE SP 2024-2029: from generation to implementation



ISPE SP 2024-2029: from generation to implementation



Inspire

Objective 1. Inspire ISPE members and leaders to engage with emerging and innovative topics – to learn about the topic, advocate scientific policy, facilitate collaboration, and to drive application and integration into practice

Goal 1.1: Throughout 2024-2029, continue transparent calls for leaders and members to engage in strategic efforts

Goal 1.2: Throughout 2025-2029, >50% of plenaries, symposia/workshops at each meeting, webinars, and engagements with collaborating organizations and at least two pre-conference courses per year are related to emerging and innovative topics and/or strategic efforts

Core Group:
Susan dosReis – SPC Champion
Gillian Caughey – Board Member
Yoshiaki Uyama – Board Member
Jennifer Christian – Executive Committee Sponsor

LEAD: Public Policy Committee

LEAD: Education Committee

pharmacoepi.org

Inspire

Objective 2. Share past successes, expertise, and innovation while leading novel integrations of epidemiology and public health in the development, research, and use of medical products and interventions

Goal 2.1: By 2025, establish a communication plan which emphasizes publicizing achievements aligned with this strategic plan, internal and external to ISPE

Goal 2.2: By 2029, develop at least 5 position statements from ISPE showcasing expertise and innovation in pharmacoepidemiology

∎ispe

Core Group: Jennifer Lund – SPC Champion Keiko Asao – Board Member Mette Norgaard – Board Member Mary Beth Ritchey – Executive Committee Sponsor

LEAD: Archives & History Committee

LEAD: : Publications & Communications Committee

pharmacoepi.org

Secure

Objective 3. Maximize utility and flexibility of organizational structure and activities to achieve mission and vision in a timely and efficient fashion

Goal 3.1: By 2026, complete a review of the organization structure and activities of ISPE; by 2028, implement any needed modifications to enhance future opportunities to achieve mission and vision

Goal 3.2: In 2025, implement onboarding for members and leaders to facilitate clear understanding of expectations, provide transparency and information flow, and encourage engagement that is aligned with ISPE mission, vision, and strategic plan Core Group: Elisabetta Patorno – SPC Champion Christopher Rentsch – Board Member Marianne Cunnington – Board Member Mary Beth Ritchey – Executive Committee Sponsor

LEAD: Executive Committee

LEAD: : Strategic Planning Committee

pharmacoepi.org

Secure

Objective 4. Identify and utilize opportunities to diversify financial and resource investments to further the ISPE mission and strategic activities that are aligned with our future vision.

Goal 4.1: By 2029, at least 40% of revenue generation is through channels not yet included in ISPE portfolio

Core Group: Jennifer Christian – SPC Champion, Executive Committee Sponsor Nickolas Everage, VP Finance Elect Andrea Margulis – Board Member Jeremy Rassen – Board Member

LEAD: Finance Committee

Goal 4.2: By 2026, improve ISPE technology resources and practices to streamline communication and procedures

LEAD: Executive Committee/ Management Company

ispe

pharmacoepi.org

Prepare

Objective 5. Increase opportunities for engagement and enhance leadership capacity for scientific exchange, collaboration, and communication globally and across disciplines

Core Group: Yasser Albogami – SPC Champion Juan M Hincapie-Castillo – Board Member Jennifer Lund – Board Member Ursula Kirchmayer – Executive Committee Sponsor

Overarching Capacity Building

Goal 5.1: By 2025, intentionally incorporate capacity-building into at least 90% of strategic efforts

Goal 5.2: By 2026, establish virtual meeting engagement practices for conferences and ISPE community meetings

Goal 5.3: By 2029, award at least 5 new FISPE to members from Africa, LATAM, and Gulf regions

LEAD: Global Development Committee

LEAD: Strategic Planning Committee

LEAD: Sustainability Committee

LEAD: Fellowship & Awards Committee

pharmacoepi.org

Prepare

Objective 6. Create diverse development opportunities for all stages of career, with emphasis on creating new opportunities for early and mid-career while maintaining opportunities for students

Goal 6.1: By 2026, develop and implement quantified expectations for involvement in at least 3 activities per year to maintain "active" FISPE status

Goal 6.2: By 2025, identify opportunities for increasing engagement in ISPE by career stage

Core Group: Daniela Moga – SPC Champion Kris Filion - Board Member Elisabetta Patorno - Board Member Lisa Pont – Executive Committee Sponsor

LEAD: Strategic Planning Committee

LEAD: Membership Committee

Empower

Objective 7. Develop and deploy engagement strategies to better include diverse perspectives and geographic regions into the field of pharmacoepidemiology

Goal 7.1: By 2025, update strategy for ISPE meetings: (a) Modify ISPE Annual Meeting location parameters – rotate between more than just North America and Europe; (b) Designate funding and calendarization for set number of regional meetings per year; (c) Designate track at ISPE Annual Meeting for regional interests

Goal 7.2: By 2029, increase (a) Number of new members who do not have degree in epidemiology, (b) Number of members who study medical interventions/products other than medicines, and (c) Number of members outside of North America or Europe by at least 20% each

Core Group:
Yasser Albogami – SPC Champion
Elisabetta Patorno – SPC
Daniela Moga – Board Member
Efe Eworuke – Board Member
Ursula Kirchmayer – Executive Committee Sponsor

LEAD: Meetings Oversight Committee

LEAD: Development Committee

pharmacoepi.org 12

Empower

Objective 8. Engage external partnerships to ensure that ISPE as an organization is included in global conversations about conduct of pharmacoepidemiology studies and translation of results into public health policy and clinical practice.

Goal 8.1: By 2026, develop and implement plan to increase advocacy globally that accounts for differing context and needs

Goal 8.2: Complete at least one activity each year (2025-2029) that is aligned with ISPE mission, vision, and strategic efforts in at least 90% of ongoing external partnerships

Core Group: Blánaid Hicks – SPC Champion Jessica Franklin - Board Member Stine Hasling Mogensen - Board Member Lisa Pont – Executive Committee Sponsor

LEAD: Public Policy Committee

LEAD: Executive Committee, delegating Liaisons





Roles & Responsibilities

Generation of the Implementation Plans

SP 2024-2029 IMPLEMENTATION

CORE GROUP

responsible for developing and overseeing the implementation plans for each Objective

LEAD

COMMITTEE, responsible for the implementation of the tactics to achieve a strategic Goal. They may create a subcommittee and are tasked with organizing the Goal-specific working group and ensuring timely achievement of the Goal. They will propose a Chair and Vice Chair of the activity to be approved by the Exec/Board

GOAL-SPECIFIC WORKING GROUP:

coordinated by the LEAD and comprising representatives from other ISPE Communities. Their involvement may differ depending on the tactics being pursued pharmacoepi.org

ispe

Roles & Responsibilities

LEAD Committee

- Revise the assigned Goal
- Create a Goal-specific working group, involving ISPE communities
- Communicate chair and co-chair of the working group to EXEC
- Elaborate tactics to
 - o prioritize and establish an overall Goal-specific timeline
 - propose changes, e.g. introducing additional tactics, subject to endorsement by the Core Group and approval by Exec
- Prepare quarterly communication of the progress upon request
- Include a progress report in the Committee's Board reports in April and August
- Keep the Objective-specific Core Group in the loop (e.g., for obstacles, requests etc.)

Tools

Implementation Plans

International Society for Pharmacoepidemiolog

STRATEGIC PLAN 2024-29

Proposals for implementation of the objectives

Guidance document

INTERNATIONAL Society for Pharmacoepidemiology

VADEMECUM for the implementation of the objectives of the "Strategic Plan 2024-2029"

The following document is intended as a guidance for the implementation of the ISPE Strategic Plan 2024-2029; it provides a summary and clarification of key components based on the roles and processes as described.

17

Progress Tracker Dashboard



ispe



For any communication, please write to

info@pharmacoepi.org

pharmacoepi.org